BPC-157 in Clinical Trials for IBD: Comprehensive Animal Evidence Supporting Human Testing. Inflammopharmacology.Study breakdown PubMed 7RPEP-03909Sikiric, Predrag et al
It is the agency saying the formal vehicle that put them on Category 2 is gone, and the substances now have to be evaluated again through a fresh process
Colchicine, Neomycin, Aminosalicylic Acid, H2-blockers (e.g., Ranitidine), and Proton Pump Inhibitors (PPIs, e.g., Omeprazole): These oral medications can all interfere with the intestinal absorption of dietary B12, making the need for injectable B12 more pronounced
That is not a marketing claim
Whether you are just starting your research or are ready to begin a medically supervised program, we are here to provide the expertise and empathy you need